A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Archives of Pediatrics & Adolescent Medicine

• Publication date

  1998-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/ARCHPEDI.152.4.358PMID 9559712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Assessing Psychological Trauma and PTSD

  1999cited by this paper
• Children in danger: Coping with the consequences of community violence

  1997cited by this paper
• Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants with Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis

  1997cited by this paper
• Lisrel 8: User's Reference Guide

  1997cited by this paper
• Assessing psychological trauma and PTSD

  1997cited by this paper
• Respiratory syncytial virus immune globulin intravenous: Indications for use

  1997cited by this paper
• Respiratory Syncytial Virus Immune Globulin: A Cost-Effectiveness Analysis

  1996influential reference
• Searching for resilience among African-American youth exposed to community violence: theoretical issues.

  1996cited by this paper
• Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children.

  1996cited by this paper
• Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin.

  1996influential reference
• A beginner's guide to structural equation modeling

  1996cited by this paper
• Health status of well vs ill adolescents.

  1996cited by this paper
• Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease.

  1995cited by this paper
• Users' guides to the medical literature. IX. A method for grading health care recommendations. Evidence-Based Medicine Working Group.

  1995cited by this paper
• The number needed to treat: a clinically useful measure of treatment effect

  1995cited by this paper
• Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies

  1995cited by this paper
• The effects of exposure to violence on young children.

  1995cited by this paper
• Willingness to pay for antenatal carrier screening for cystic fibrosis.

  1995cited by this paper
• Valuing health care: Valuing health care benefits in money terms

  1995cited by this paper
• Users' Guides to the Medical Literature: IX. A Method for Grading Health Care Recommendations

  1995cited by this paper
• Who benefits from medical interventions?

  1994cited by this paper
• Factors associated with the use of violence among urban black adolescents.

  1994cited by this paper
• Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: A prospective, double‐blind, randomized trial

  1994cited by this paper
• A trial of RSV immune globulin in infants and young children: the FDA's view.

  1994cited by this paper
• Toward an ecological/transactional model of community violence and child maltreatment: consequences for children's development.

  1993cited by this paper
• Children's exposure to community violence: following a path from concern to research to action.

  1993cited by this paper
• The NIMH community violence project: II. Children's distress symptoms associated with violence exposure.

  1993cited by this paper
• The NIMH community violence project: I. Children as victims of and witnesses to violence.

  1993cited by this paper
• The prevalence and consequences of exposure to violence among African-American youth.

  1993cited by this paper
• Silent victims. Children who witness violence.

  1993cited by this paper
• Intravenous immune globulin for the prevention of nosocomial infection in low‐birth‐weight neonates

  1993cited by this paper
• Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children

  1993influential reference
• Book Reviews

  1993cited by this paper
• Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

  1993cited by this paper
• Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates.

  1992cited by this paper
• Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada.

  1992cited by this paper
• Co-victimization of African-American children who witness violence: effects on cognitive, emotional, and behavioral development.

  1991cited by this paper
• The use of intravenous immune globulin in immunodeficiency diseases.

  1991cited by this paper
• Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation.

  1991cited by this paper
• Risk Reduction From Low Osmolality Contrast Media: What Do Patients Think It is Worth?

  1990cited by this paper
• An assessment of clinically useful measures of the consequences of treatment.

  1988cited by this paper
• What Do Patients Value?: Willingness to Pay for Ultrasound in Normal Pregnancy

  1985cited by this paper
• Children of War

  1983cited by this paper
• Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection.

  1973cited by this paper

• Decision analysis and reinforcement learning in surgical decision-making.

  2020cites this paper
• Can we improve the targeting of respiratory syncytial virus (RSV) prophylaxis in infants born 32–35 weeks’ gestational age with more informed use of risk factors?

  2015cites this paper
• Adherence to Immunoprophylaxis Regimens for Respiratory Syncytial Virus Infection in Insured and Medicaid Populations.

  2013cites this paper
• Morbidity and Mortality Weekly Report

  2012cites this paper
• Cost Effectiveness of Respiratory Syncytial Virus Prophylaxis

  2012cites this paper
• Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria

  2012cites this paper
• A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis

  2010cites this paper
• syncytial virus : a cost-effectiveness analysis Passive immunisation against respiratory

  2010cites this paper
• Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis

  2010cites this paper
• WITHDRAWN: Immunoglobulin for preventing respiratory syncytial virus infection.

  2007cites this paper
• Kapitel 5 – Säuglingsperiode

  2007cites this paper
• Diagnosis and management of bronchiolitis.

  2006cites this paper
• Immunoglobulin for preventing respiratory syncytial virus infection.

  2006cites this paper
• Diagnosis and Management of Bronchiolitis

  2006cites this paper
• Anticipated Costs of Hospitalization for Respiratory Syncytial Virus Infection in Young Children at Risk

  2004cites this paper
• Economic Analysis of Palivizumab in Infants With Congenital Heart Disease

  2004cites this paper
• Cost-effectiveness analysis based on the number-needed-to-treat: common sense or non-sense?

  2004cites this paper
• Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee.

  2004cites this paper
• Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants

  2003cites this paper
• Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

  2003cites this paper
• Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.

  2003cites this paper
• Current strategies in the prevention of respiratory syncytial virus disease.

  2003cites this paper
• Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.

  2002cites this paper
• Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis.

  2002cites this paper
• Respiratory syncytial virus immune globulin: Decisions and costs

  2001cites this paper
• Costs and respiratory syncytial virus.

  2001cites this paper
• Prevention of respiratory syncytial virus infections.

  2001cites this paper
• New modalities for preventing and treating influenza

  2001cites this paper
• Management of respiratory syncytial virus infection

  2001cites this paper
• Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

  2000cites this paper
• Treatment and prevention of respiratory syncytial virus infection

  2000cites this paper
• Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality.

  2000cites this paper
• Palivizumab (synagis): counting "costs" and values.

  2000cites this paper
• Prophylaxis for respiratory syncytial virus with respiratory syncytial virus‐immunoglobulin intravenous among preterm infants of thirty‐two weeks gestation and less: reduction in incidence, severity of illness and cost

  2000cites this paper
• A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease

  2000cites this paper
• Outcome of respiratory syncytial virus infection and a cost–benefit analysis of prophylaxis

  2000cites this paper
• The Critical Role of Population-Based Epidemiology in Cost-Effectiveness Research

  2000cites this paper
• Prevention of bronchiolitis.

  2000cites this paper
• Users' guides to the medical literature: XVI. How to use a treatment recommendation. Evidence-Based Medicine Working Group and the Cochrane Applicability Methods Working Group.

  1999cites this paper
• Users' guides to the medical literature XVI. How to use a treatment recommendation

  1999cites this paper
• Magnetoencephalographic Patterns of Epileptiform Activity in Children With Regressive Autism Spectrum Disorders

  1999cites this paper
• Tanner Staging and Pornography

  1999cites this paper
• Fever without apparent source on clinical examination, lower respiratory infections in children, and other infectious diseases.

  1999cites this paper
• IMpact-RSV Study Group report.

  1999cites this paper
• Active and passive immunisation against respiratory syncytial virus

  1999cites this paper
• Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.

  1999influential citation
• Respiratory syncytial virus: A continuing culprit and conundrum.

  1999cites this paper
• Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.

  1999cites this paper
• Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm Infants

  1999cites this paper
• Observer Bias in Acellular Pertussis Vaccine Trials

  1999cites this paper
• RSV Immune Globulin Prophylaxis: Is an Ounce of Prevention Worth a Pound of Cure?

  1999cites this paper
• Magnetoencephalographic Patterns of Epileptiform Activity in Children With Regressive Autism Spectrum Disorders

  1999cites this paper
• Advances in antiviral therapy.

  1999cites this paper
• Upper respiratory tract infections.

  1999cites this paper
• Foster Care Problem

  1999cites this paper
• IMpact-RSV Study Group Report

  1999cites this paper
• Development of local guidelines for prevention of respiratory syncytial viral infections.

  1999cites this paper
• Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV

  1998cites this paper